Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00. The stock has shown ...
Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming ...
Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at $2.90.Invest ...
Absci Corp (ABSI) stock saw a modest uptick, ending the day at $2.9 which represents a slight increase of $0.10 or 3.57% from the prior close of $2.8. The stock opened at $2.86 and touched a low of $2 ...
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...
Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial ...
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.14, a high estimate of $10.00, and a low estimate of $5.00. This current average represents a 2.06% ...
Absci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design ...
On Tuesday, Absci Corp (ABSI) stock saw a decline, ending the day at $2.71 which represents a decrease of $-0.14 or -4.91% from the prior close of $2.85. The stock opened at $2.85 and touched a low of ...